In acute coronary syndrome (ACS), a prasugrel (Effient)-based antiplatelet regimen passed muster for reducing bleeding ...

The lower rate of net adverse clinical events was driven by less bleeding in those on 1 month of prasugrel-based DAPT.

In summary, prasugrel (60 mg loading dose and 10 mg maintenance dose) is currently approved for patients with ACS undergoing PCI, and should be administered only after the coronary anatomy has ...

This was a single-centered, open-label, parallel-design study. Subjects received a single loading dose (LD) of prasugrel followed by once-daily maintenance dose (MD) for 10 d. They were enrolled ...

Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention.

In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg ...

But the new drug, prasugrel (Effient), is also more likely to cause potentially fatal bleeding. Overall, prasugrel may be superior to the approved dose of the older drug, clopidogrel (Plavix), in ...

When patients receive a loading dose of prasugrel prior to switching from clopidogrel, the reduction in platelet function occurs within two hours, report investigators. "Basically, the pivotal ...

June 11, 2012 (La Jolla, California) — The current US recommendations for discontinuing antiplatelet therapy with prasugrel (Effient, Eli Lilly/Daiichi Sankyo) prior to cardiac surgery ...

11.0 percent, respectively, p<0.0001).(1) This corresponds to a 2.7 percent absolute risk reduction for patients treated with prasugrel. The results of this analysis, which also examined ...

Review the side-effects of Prasugrel as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of ...